Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Horizons Psychedelic Stock Index ETF (PSYK.NE)

Horizons Psychedelic Stock Index ETF (PSYK.NE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NEO]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NEO]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Horizons ETF
  • Assets Under Management 15,268,600
  • Shares Outstanding, K 1,996
Trade PSYK.NE with:
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Management Fee 0.85%
  • Asset Class Equity

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.5000 +17.69%
on 12/29/22
8.3700 -8.60%
on 01/18/23
+0.6800 (+9.76%)
since 12/23/22
3-Month
6.5000 +17.69%
on 12/29/22
8.9500 -14.53%
on 11/02/22
-0.8400 (-9.89%)
since 10/27/22
52-Week
6.5000 +17.69%
on 12/29/22
17.0400 -55.11%
on 02/10/22
-7.5500 (-49.67%)
since 01/27/22

Most Recent Stories

More News
PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund

TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce...

PSYK.NE : 7.6500 (-0.52%)
PSYK : 18.30 (+0.13%)
PHRRF : 0.0968 (+1.89%)
PHRM.CN : 0.1300 (unch)
Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose

VANCOUVER, British Columbia, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...

PSYK.NE : 7.6500 (-0.52%)
AGN.CN : 2.1000 (unch)
AGNPF : 1.5955 (-0.28%)
Optimi Health Appoints New Chief Executive Officer

VANCOUVER, British Columbia, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“ Optimi ” or the “ Company ”), developers of a vertically integrated...

PSYK.NE : 7.6500 (-0.52%)
OPTI.CN : 0.2400 (+4.35%)
OPTHF : 0.1740 (+2.41%)
Algernon Pharmaceuticals Announces Small Cell Lung Cancer Ifenprodil Research Program and Appoints Dr. William North as Lead Consultant

VANCOUVER, British Columbia, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical...

PSYK.NE : 7.6500 (-0.52%)
AGN.CN : 2.1000 (unch)
AGNPF : 1.5955 (-0.28%)
Optimi Health Updates Launch of Online Functional Mushroom Sales

VANCOUVER, British Columbia, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional...

PSYK.NE : 7.6500 (-0.52%)
OPTI.CN : 0.2400 (+4.35%)
OPTHF : 0.1740 (+2.41%)
Algernon Pharmaceuticals Announces Exclusive Licensing Agreement with Dartmouth College

VANCOUVER, British Columbia, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical...

PSYK.NE : 7.6500 (-0.52%)
AGN.CN : 2.1000 (unch)
AGNPF : 1.5955 (-0.28%)
Optimi Health Strengthens Clinical and Regulatory Expertise

VANCOUVER, British Columbia, July 27, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), as part of its strategic aim to fully investigate...

PSYK.NE : 7.6500 (-0.52%)
OPTI.CN : 0.2400 (+4.35%)
OPTHF : 0.1740 (+2.41%)
Algernon Pharmaceuticals Announces 70% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

VANCOUVER, British Columbia, July 07, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF) (the “ Company ” or “ Algernon ”), a clinical stage pharmaceutical...

PSYK.NE : 7.6500 (-0.52%)
AGN.CN : 2.1000 (unch)
AGNPF : 1.5955 (-0.28%)
Algernon Pharmaceuticals Announces it Will Not Advance Ifenprodil into Phase 3 Trial for COVID-19

VANCOUVER, British Columbia, July 06, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...

PSYK.NE : 7.6500 (-0.52%)
AGN.CN : 2.1000 (unch)
AGNPF : 1.5955 (-0.28%)
Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021

VANCOUVER, British Columbia, June 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to announce that...

PSYK.NE : 7.6500 (-0.52%)
AGN.CN : 2.1000 (unch)
AGNPF : 1.5955 (-0.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Fund Summary

The Horizons Psychedelic Stock Index ETF seeks to replicate the performance of the North American Psychedelics Index, net of expenses.

See More

Key Turning Points

3rd Resistance Point 7.7700
2nd Resistance Point 7.7300
1st Resistance Point 7.6900
Last Price 7.6500
1st Support Level 7.6100
2nd Support Level 7.5700
3rd Support Level 7.5300

See More

52-Week High 17.0400
Fibonacci 61.8% 13.0137
Fibonacci 50% 11.7700
Fibonacci 38.2% 10.5263
Last Price 7.6500
52-Week Low 6.5000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar